Department of Dental Medicine, Karolinska Institutet, 14152 Stockholm, Sweden.
Department of Laboratory Medicine, Karolinska Institutet, 14152 Stockholm, Sweden.
Cells. 2020 Jun 16;9(6):1471. doi: 10.3390/cells9061471.
Chronic infection with viral hepatitis is a major risk factor for liver injury and hepatocellular carcinoma (HCC). One major contributing factor to the chronicity is the dysfunction of virus-specific T cell immunity. T cells engineered to express virus-specific T cell receptors (TCRs) may be a therapeutic option to improve host antiviral responses and have demonstrated clinical success against virus-associated tumours. This review aims to give an overview of TCRs identified from viral hepatitis research and discuss how translational lessons learned from cancer immunotherapy can be applied to the field. TCR isolation pipelines, liver homing signals, cell type options, as well as safety considerations will be discussed herein.
慢性病毒性肝炎感染是肝损伤和肝细胞癌（HCC）的主要危险因素。导致慢性感染的一个主要因素是病毒特异性 T 细胞免疫功能障碍。表达病毒特异性 T 细胞受体（TCR）的 T 细胞可能是改善宿主抗病毒反应的一种治疗选择，并已在对抗病毒相关性肿瘤的治疗中取得了临床成功。本文旨在综述从病毒性肝炎研究中鉴定的 TCR，并讨论从癌症免疫疗法中获得的转化经验教训如何应用于该领域。本文将讨论 TCR 的分离管道、肝脏归巢信号、细胞类型选择以及安全性考虑等方面。
